)
Bausch + Lomb (BLCO) investor relations material
Bausch + Lomb Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue was $1.375B, up 7% reported and 8% at constant currency; adjusted EBITDA rose 34% to $325M and all three segments grew.
Full-year 2026 revenue and adjusted EBITDA guidance increased on Q3 strength and an improved outlook for the remainder of the year.
Performance marked a fourth consecutive quarter meeting Investor Day commitments; interim CEO priorities include profitability, efficiency, disciplined innovation investment and Vision 2027 targets.
Financial highlights
Q3 revenue rose $94M YoY; volume added $63M and pricing $31M, partly offset by $6M of FX headwind and $2M from divestitures and discontinuations.
GAAP operating income was $155M versus $95M; attributable net income was $32M versus a $28M loss, and adjusted net income was $123M versus $66M.
Adjusted gross margin increased 300 bps to 64.7%, including a one-time ~$14M tariff refund; excluding the refund, margin was 63.6%.
Q3 operating cash flow was $233M and free cash flow was $178M after $55M of capex; 9M operating cash flow reached $418M.
Outlook and guidance
FY26 revenue guidance rose to $5.450B–$5.550B, with constant-currency growth of 6.1%–8.0%; underlying outlook increased $15M, partly offset by $5M lower FX tailwinds.
FY26 adjusted EBITDA guidance increased $65M to $1.090B–$1.140B; midpoint implies ~20.3% margin and 25% growth.
FY26 assumptions include adjusted gross margin of 62.5%–63.0%, net interest expense of ~$365M, adjusted tax rate of ~18% and capex of ~$285M.
Management remains focused on meeting or exceeding three-year Investor Day targets; the 2028 adjusted EBITDA margin target is 23%.
- FY23 growth broadened across segments as margin pressure and supply disruption persisted.BLCO
Q4 2023 - Dual-action dry eye and BL1332 pain therapies show rapid efficacy, safety, and $2B+ peak sales potential.BLCO
Study result - Q2 2026 delivered 9% revenue growth, margin expansion, and raised full-year guidance.BLCO
Q2 2026 - Operational excellence and breakthrough innovation drive growth and margin expansion through 2028.BLCO
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Bioactive and myopia control lenses target 2028–2029 launches, with peak sales up to $500M.BLCO
R&D Day 2026 - All proposals voted on were approved, with final results to be filed in a Form 8-K.BLCO
AGM 2026 - Q1 2026 revenue up 9%, adjusted EBITDA up 59%, and full-year guidance raised.BLCO
Q1 2026 - BL1107 and ELIOS advance as innovative glaucoma solutions, targeting major unmet needs.BLCO
Status update - Q3 2025 revenue rose 7% to $1.281B, with strong segment growth and $28M net loss.BLCO
Q3 2025
Next Bausch + Lomb earnings date
Next Bausch + Lomb earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)